Treatment outcomes of diffuse large B-cell non-Hodgkin{u2019}s lymphoma presenting to Tanta cancer center / Ayman Elsayed Elfakharany ; Supervised Ahmed Abdelmabood Zeeneldin , Ayman Abdelsamie Gaber , Amgad Ahmad Shaheen
Material type: TextLanguage: English Publication details: Cairo : Ayman Elsayed Elfakharany , 2014Description: 155 P. : charts ; 25cmOther title:- نتائج علاج أورام الغدد الليمفاوية اللاهودجكنية المتسعة كبيرة الخلية من النوع باء في مركز أورام طنطا [Added title page title]
- Issued also as CD
Item type | Current library | Home library | Call number | Copy number | Status | Date due | Barcode | |
---|---|---|---|---|---|---|---|---|
Thesis | قاعة الرسائل الجامعية - الدور الاول | المكتبة المركزبة الجديدة - جامعة القاهرة | Cai01.19.04.M.Sc.2014.Ay.T (Browse shelf(Opens below)) | Not for loan | 01010110065140000 | |||
CD - Rom | مخـــزن الرســائل الجـــامعية - البدروم | المكتبة المركزبة الجديدة - جامعة القاهرة | Cai01.19.04.M.Sc.2014.Ay.T (Browse shelf(Opens below)) | 65140.CD | Not for loan | 01020110065140000 |
Thesis (M.Sc.) - Cairo University - National Cancer Institute - Department of Medical Oncology
Introduction: DLBC-NHL is the most common lymphoid neoplasm and constitutes almost 50% of all NHLs. Methods: This thesis includes 485 patients was conducted to study the outcomes in patients with DLBC-NHL among patients treated at Tanta Cancer Center (TCC) between 2003 and 2006 and followed up till March 2014. Results: 88% of patients received CTx being CHOP in 72.4% of cases. CR was achieved in 62.1%, PFS was 21.4 months. The median OS was 20 months. Conclusions: Outcomes of DBLC-NHL at TCC is comparable to those in the literature. Adding Rituximab is recommended to further improve the treatment
Issued also as CD
There are no comments on this title.